Join White as he discusses the burden cataract post-operative regimens place on both patients and staff, and ways to “stop the madness.” He also gives a history of cataract post-op and the breakthroughs that led to today’s most common regimens.

• Disclaimer :09
• Intro :24
• Let’s talk about post-op drop regimens for cataract surgery :35
• Financial disclosures :53
• Asking specialists from around the country two important questions 1:40
• Question 1: ”What is your definition of health?” 3:05
• The “best” answer 3:47
• Question 2: ”What is your perioperative cataract surgery drop regimen?” 4:12
• The most common regimens 5:18
• The rise in publications about using antibiotics inside the eye 9:23
• “Revolutionaries” who stopped using steroids post-op to reduce patient drop burden 10:19
• One drop of topical NSAID a day vs. steroids post-op 12:23
• White’s study: moxifloxacin vs. moxifloxacin and dexamethasone 14:27
• How can we get to a “dropless” situation? 17:40
• Why are patients continuing with topical antibiotics when they’re also using intracameral antibiotic injections? 20:16
• There should be fewer eye drops and medications in eye drops surrounding cataract surgery 22:05
• “Stop the madness” - Reducing the post-op medication burden on both patients and staff 24:58
• Outro 25:43

We’d love to hear from you! Send your comments/questions to Dr. White at ophthalmology@healio.com. Follow us on Twitter @Healio_OSN and @DarrellWhite.

Disclosures: White reports no relevant financial disclosures.

What is unnecessary care? What does it look like in the real-world? Join White as he defines “medically unnecessary care” and shares a personal story.

• Disclaimer :09
• Intro :24
• Today we’ll talk about unnecessary care :38
• Financial disclosures :52
• Defining unnecessary care, or medically unnecessary care 1:05
• Unnecessary care in the real-world setting 2:24
• A case of “unnecessary care” 6:50
• Thanks for listening 19:40

We’d love to hear from you! Send your comments/questions to Dr. White at ophthalmology@healio.com. Follow us on Twitter @Healio_OSN @DarrellWhite

Disclosures: White reports no relevant financial disclosures.

Join White as he discusses the history of cataract surgery and where femtosecond laser-assisted cataract surgery, or FLACS, fits in. He also explains what he believes to be follies of FLACS and why some people continue to use this procedure.

• Disclaimer :09
• Intro :24
• Today we’ll talk about femtosecond laser-assisted cataract surgery, or FLACS :36
• Financial disclosures :57
• The history of cataract surgery and where FLACS fits in 1:21
• The lens supplies about 1/3 of the focusing ability of the human eye 3:35
• Scheie Eye Institute 5:42
• The discovery of poly(methyl methacrylate) 6:14
• Extracapsular cataract extraction 7:14
• Cataract surgery moves almost entirely to posterior chamber 7:44
• The YAG laser 18:40
• Phacoemulsification 19:21
• All of these procedures were paid for by health insurance 11:41
• The Crystalens 17:00
• A petition for patients to have the right to pay to upgrade their implant experience 17:37
• The era of refractive cataract surgery 19:03
• A false timeline 19:32
• Comparing things properly, you find a small difference between two surgeries 22:29
• The impressive engineering of femtosecond lasers 23:30
• Why do people use the femtosecond laser surgery? 24:53
• I do a bit of work as a defense expert in malpractice cases 26:42
• There are some bright spots here 29:21
• Calling out two groups who don’t let patients decide whether they want FLACS 30:48
• I have respect for them, but I don’t think there is justification for doing FLACS based on outcomes 36:13
• Throwing a bone to the proponents of FLACS 37:14
• That’s my take on FLACS 38:56

We’d love to hear from you! Send your comments/questions to Dr. White at ophthalmology@healio.com. Follow us on Twitter @Healio_OSN @DarrellWhite

Disclosures: White reports being a consultant to Allergan, Bruder, EyePoint, Eyevance, Kala, Novartis, Ocular Therapeutix, Omeros, Rendia, Sun and Tearlab; speaker for Allergan, Eyevance, Kala, Novartis, Omeros and Sun; and ownership in Ocular Science.